Kim Berger is the Director of Business Development for the recombinant protein manufacturing business at Grifols with over 30 years of experience in biotech. Before joining Grifols she managed the license agreement portfolio for Novartis, where she provided business analysis for the negotiation strategy of patent infringement litigation and key supply contracts. She was also a member of the Chiron scientific team that “walked the genome” of the NANB/Hepatitis C virus and expressed HCV recombinant antigens in various expression systems. Kim holds a B.S. in genetics from the University of California, Berkeley.